Profile data is unavailable for this security.
About the company
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases, dermatology, and healthtech. Its development pipeline includes Distal Ulcerative Colitis, Bile Acid Diarrhea, Solid Tumors, and AI Augmented Endoscopy. The Company's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, which is used for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which is used for the treatment of travelers’ diarrhea (TD); Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy, and Winlevi, which is used for the treatment of acne. It also develops medical devices to assist with clinical decision-making.
- Revenue in CHF (TTM)248.35m
- Net income in CHF124.03m
- Incorporated--
- Employees322.00
- LocationCosmo Pharmaceuticals NVRiverside II, Sir John Rogerson's QuayDUBLIN IrelandIRL
- Phone+353 18170370
- Websitehttps://www.cosmopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Granules India Ltd | 415.94m | 46.55m | 1.06bn | 4.12k | 22.68 | 3.06 | 15.65 | 2.54 | 20.68 | 20.68 | 184.80 | 153.19 | 0.7613 | 1.28 | 4.65 | -- | 8.52 | 10.20 | 13.05 | 15.66 | 61.49 | 51.75 | 11.19 | 11.64 | 0.8849 | 6.97 | 0.2814 | 7.69 | -0.5494 | 11.52 | 23.74 | 9.64 | 25.38 | 8.45 |
| Marksans Pharma Ltd | 243.43m | 35.32m | 1.07bn | 2.00k | 30.30 | 4.68 | 24.75 | 4.40 | 8.40 | 8.40 | 57.89 | 54.44 | 0.886 | 1.56 | 5.28 | -- | 12.93 | 14.15 | 15.27 | 17.41 | 56.39 | 52.46 | 14.59 | 14.58 | 2.85 | 38.19 | 0.1145 | 7.72 | 20.46 | 18.25 | 21.32 | 26.60 | 23.73 | 51.57 |
| Harbin Pharmaceutical Group Co Ltd | 1.80bn | 73.90m | 1.08bn | 9.85k | 14.62 | 1.75 | -- | 0.5998 | 0.2641 | 0.2641 | 6.44 | 2.21 | 1.15 | 6.35 | 3.37 | -- | 5.09 | 1.58 | 12.71 | 4.28 | 27.01 | 24.86 | 4.44 | 1.51 | 1.18 | 32.77 | 0.331 | 0.00 | 4.65 | 6.47 | 59.10 | 62.32 | 20.92 | -- |
| Cosmo Pharmaceuticals NV | 248.35m | 124.03m | 1.09bn | 322.00 | 8.16 | 2.14 | 8.03 | 4.38 | 7.60 | 7.60 | 15.18 | 28.97 | 0.455 | 3.27 | 11.26 | 771,767.40 | 22.71 | 4.65 | 24.53 | 5.15 | 83.00 | 68.39 | 49.92 | 26.16 | 3.91 | -- | 0.0043 | 49.72 | 187.55 | 33.68 | 1,335.61 | -- | -20.06 | -- |
| Sanofi Consumer Healthcare India Ltd | 63.66m | 15.62m | 1.11bn | 583.00 | 70.93 | -- | 68.65 | 17.40 | 73.08 | 73.08 | 297.82 | -- | -- | -- | -- | 11,765,010.00 | -- | -- | -- | -- | 75.96 | -- | 24.54 | -- | -- | 57.49 | -- | -- | 30.45 | -- | 9.76 | -- | -- | -- |
| Sihuan Pharmaceutical Holdings Group Ltd | 211.06m | -24.05m | 1.12bn | 2.67k | -- | 2.32 | -- | 5.30 | -0.0256 | -0.0256 | 0.2245 | 0.5175 | 0.1723 | 1.11 | 4.54 | 779,898.90 | -4.27 | -3.60 | -7.06 | -5.05 | 65.32 | 73.13 | -24.80 | -19.74 | 1.57 | -4.07 | 0.1489 | -- | 2.18 | -7.96 | -301.10 | -- | -20.58 | 3.60 |
| ANI Pharmaceuticals Inc | 536.93m | -18.11m | 1.12bn | 897.00 | -- | 3.36 | 26.41 | 2.09 | -1.19 | -1.19 | 34.46 | 20.46 | 0.6109 | 2.18 | 3.43 | 751,469.30 | -1.91 | -2.99 | -2.25 | -3.49 | 59.34 | 58.84 | -3.12 | -6.12 | 1.98 | 0.6182 | 0.5841 | -- | 26.20 | 24.36 | -230.19 | -- | 19.60 | -- |
| GuangYuYuan Chinese Herbal Medicn Co Ltd | 143.92m | 10.75m | 1.12bn | 1.74k | 104.54 | 6.19 | -- | 7.81 | 0.1976 | 0.1976 | 2.65 | 3.34 | 0.517 | 0.6405 | 3.24 | 746,507.10 | 3.98 | -2.57 | 6.04 | -3.94 | 68.68 | 68.69 | 7.69 | -6.95 | 1.13 | 10.43 | 0.0442 | -- | -4.87 | 0.071 | -17.35 | -10.56 | -36.84 | -- |
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 30 Jun 2025 | 505.27k | 2.88% |
| The Vanguard Group, Inc.as of 02 Jul 2025 | 330.93k | 1.89% |
| Z�rcher Kantonalbank (Investment Management)as of 30 May 2025 | 211.03k | 1.20% |
| Artisan Partners LPas of 31 Mar 2025 | 122.97k | 0.70% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 116.44k | 0.66% |
| JPMorgan Asset Management (UK) Ltd.as of 31 May 2025 | 101.98k | 0.58% |
| Dimensional Fund Advisors LPas of 04 Jul 2025 | 91.89k | 0.52% |
| TIAA-CREF Investment Management LLCas of 30 Apr 2025 | 48.81k | 0.28% |
| 3V Asset Management AGas of 30 Apr 2024 | 41.66k | 0.24% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 34.95k | 0.20% |
